Services: Intercambio plasmático terapéutico

What It Is

Therapeutic plasma exchange separates blood into its cells and its plasma, the straw-colored fluid the cells float in. It discards the plasma and returns the cells in a replacement fluid, usually human albumin and sometimes donor plasma. An apheresis machine does the separation through a large intravenous line or a central catheter, over one to a few hours. A single course usually runs several sessions spread across days or weeks. The aim is to pull out substances dissolved in the plasma that drive a disease: rogue antibodies, immune complexes, and other large molecules. Ordinary drugs clear these slowly, or not at all.

For a defined list of diseases this is standard care, and for some it is the difference between a fatal illness and a survivable one. The aging use relies on the same machine and almost nothing else.

Anatomy

1Separating the blood

Blood is drawn from a vein or a central catheter into an apheresis machine that spins or filters it, separating the red and white cells from the plasma. The cells go back to the body continuously, and the plasma is removed. A large volume of blood sits outside the body in the tubing during the session, so the line and the machine carry most of the procedural risk.

2Removing the plasma

The removed plasma carries whatever large molecules were dissolved in it, including the autoantibodies and immune complexes that drive certain diseases. This is the therapeutic action for the established uses. One session lowers a circulating antibody within hours, faster than the body clears it, faster than most drugs act. That speed is why plasma exchange is used when a disease is moving fast.

3Replacing the volume

The plasma taken out has to be replaced, usually with a solution of human albumin, sometimes with donor plasma when clotting factors also need replacing. To keep blood from clotting inside the machine, the circuit runs on citrate, which binds calcium. That keeps the tubing clear and is also the source of the most common side effect, a temporary drop in the calcium available to the body.

How It Works

Plasma exchange removes molecules from the blood; it adds no drug. In the established diseases the target is one harmful substance floating in the plasma. In Guillain-Barre syndrome and myasthenia gravis it is an autoantibody attacking nerves. In thrombotic thrombocytopenic purpura it is an antibody against a clotting enzyme. In anti-GBM disease it is an antibody attacking the kidney and lung. Lowering that substance fast buys time, and in the fast-moving diseases it changes the outcome. The replacement fluid restores blood volume. When donor plasma is used, it also restores clotting proteins the exchange removed.

The aging idea runs on a less certain logic. Plasma composition shifts with age, and animal work suggests that some substances building up in old plasma impair tissue function. That leaves two explanations, and each points to a different treatment:

• Add young factors. If young plasma supplies something an old body has lost, the fix is to infuse young plasma.
• Remove old factors. If old plasma carries harmful factors, the fix is to remove or dilute them, which a plain albumin exchange already does.

One mouse experiment separated the two: researchers replaced half the old plasma with saline and albumin, added no young blood, and the animals still rejuvenated. That points to removal over added young factors as the active step. For where this sits among the drivers of aging, see the biology of aging.

What the Evidence Shows

For thrombotic thrombocytopenic purpura, Guillain-Barre syndrome, myasthenia gravis, anti-GBM disease, and several other autoimmune nerve and kidney disorders, plasma exchange is standard care. The American Society for Apheresis grades it first-line, Category I, on the strength of randomized trials. These diseases are the reason the procedure and the machines exist. Category I applies to one named disease at a time. The guidelines give plasma exchange no grade for aging.

The aging use is the frontier. The evidence is weaker in people than in mice. The one substantial human trial in an aging-related disease is AMBAR, in Alzheimer disease. AMBAR has two problems:

• Grifols funded it, the plasma-products company that stood to gain, and several of its authors were Grifols employees, so the result is not independent.
• Its effect on the main cognitive scale (ADAS-Cog) was a statistical trend, not a clear result (P=.06).

The only significant signal sat in the moderate-disease subgroup; the mild subgroup did not move, so the slowing overall was modest and mixed. For healthy aging, as distinct from Alzheimer disease, no completed trial shows benefit at all.

In 2019 the FDA warned that young-plasma infusions sold for aging have not been shown to help and carry the risks of any plasma transfusion.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

How it works

Plasma exchange removes circulating antibodies faster than the body or drugs can clear themStrong · mixed

In plain terms

A machine takes the liquid part of your blood out, throws it away with whatever harmful large molecules were floating in it, and gives the cells back with a replacement fluid. It lowers a circulating substance faster than the body or most drugs can.

In detail

In therapeutic plasma exchange, blood is drawn into an apheresis device that separates plasma from cellular elements by centrifugation or membrane filtration. The removed plasma carries immunoglobulins, immune complexes, paraproteins and protein-bound substances. Replacement is typically 5% human albumin, with fresh frozen plasma used when coagulation factors must also be replaced. Citrate is infused into the circuit to chelate calcium and prevent clotting. One to 1.5 plasma volumes are exchanged per session, and a treatment course is usually several sessions. The therapeutic rationale for the established indications is rapid reduction of a pathogenic plasma constituent.

The study · 1

Padmanabhan et al., Guidelines on the Use of Therapeutic Apheresis in Clinical Practice, ASFA Eighth Special Issue · J Clin Apher 2019;34(3):171-354

Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.

Sharing a young mouse's blood restored aged muscle and liver stem cells (mice)Moderate

In plain terms

When an old mouse is surgically connected to a young mouse so they share blood, the old mouse's stem cells start behaving younger. It shows that something carried in the blood can shift aging, at least in mice.

In detail

Conboy and colleagues (2005) joined the circulations of young and old mice (heterochronic parabiosis) and found that exposure to a young systemic environment restored the regenerative capacity of aged muscle satellite cells and liver progenitor cells, reactivating molecular signaling that had declined with age. This established that circulating factors, not only intrinsic cell aging, govern aspects of tissue aging. It is the foundational experiment behind the young-blood field.

The study · 1

Conboy et al., Rejuvenation of aged progenitor cells by exposure to a young systemic environment · Nature 2005;433(7027):760-764

Replacing about half of old mice's plasma with saline-albumin rejuvenated tissue, no young blood addedModerate

In plain terms

When researchers diluted old mouse blood with a simple saline-and-albumin mix and added no young blood at all, the old tissues still improved. That points to removing bad factors, not adding young ones, as a big part of what is going on.

In detail

Mehdipour and colleagues (2020) performed a neutral blood exchange in old mice, replacing roughly 50% of plasma with saline containing 5% albumin. This procedure, which adds no young plasma, improved regeneration and reduced markers of aging in muscle, liver and brain, comparable in several respects to heterochronic effects. The authors argued that dilution of pro-aging or inhibitory factors in old plasma, and possibly the replacement of albumin itself, drives the benefit. This reframes the mechanism away from young-factor transfer toward removal, and is the rationale for testing plain plasma exchange with albumin, not young-donor plasma.

The study · 1

Mehdipour et al., Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin · Aging (Albany NY) 2020;12(10):8790-8819

Autoimmune Neuro

About 78% survive TTP with plasma exchange, versus 63% with plasma infusionStrong

In plain terms

Thrombotic thrombocytopenic purpura used to kill most people who got it. Plasma exchange changed that: in the trial that set the standard, more patients survived and recovered with plasma exchange than with plasma infusion.

In detail

Rock and colleagues (1991) randomized 102 patients with thrombotic thrombocytopenic purpura, 51 to plasma exchange and 51 to plasma infusion. Plasma exchange produced more responses at the early time points and better survival, with roughly 78% of the exchange group versus 63% of the infusion group alive at six months. TTP is caused by autoantibodies against the ADAMTS13 enzyme; plasma exchange both removes the antibody and replaces the deficient enzyme, which is why exchange outperforms infusion alone. This trial established plasma exchange as first-line therapy for TTP.

The study · 1

Rock et al., Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura (Canadian Apheresis Study Group) · N Engl J Med 1991;325(6):393-397

Plasma exchange speeds Guillain-Barre recovery, with fewer left severely weak at one yearStrong

In plain terms

In Guillain-Barre syndrome, where the immune system attacks the nerves and causes rising paralysis, plasma exchange helps people recover faster and leaves fewer with lasting severe weakness.

In detail

Raphael and colleagues (2012 Cochrane review) pooled six randomized trials of plasma exchange in Guillain-Barre syndrome. Compared with supportive care, plasma exchange shortened time on a ventilator and time to recover walking, increased the proportion recovering full strength at one year, and reduced severe residual weakness, with the largest benefit when started within the first two weeks of symptoms. The mechanism is removal of the circulating autoantibodies and complement factors driving the acute demyelinating attack. Plasma exchange and intravenous immunoglobulin are considered equivalent first-line options.

The study · 1

Raphael et al., Plasma exchange for Guillain-Barre syndrome · Cochrane Database Syst Rev 2012;(7):CD001798

Apheresis guidelines rank plasma exchange first-line (Category I) for TTP, Guillain-Barre and myasthenia crisisStrong

In plain terms

Plasma exchange is a recognized standard treatment for a specific list of diseases, not a general therapy. Kidney and nerve conditions driven by rogue antibodies are where it belongs, graded by the professional apheresis society.

In detail

The ASFA Eighth Special Issue (Padmanabhan et al., 2019) grades apheresis indications by evidence quality and assigns a category from I (accepted first-line) to IV (evidence suggests harm or ineffectiveness). Plasma exchange holds Category I status for thrombotic thrombocytopenic purpura, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis (moderate-severe or crisis), anti-GBM disease (Goodpasture), and others. The guidelines are periodically updated as trial evidence accumulates. This grading is the reference standard clinicians use to decide when plasma exchange is indicated.

The study · 1

Padmanabhan et al., Guidelines on the Use of Therapeutic Apheresis in Clinical Practice, ASFA Eighth Special Issue · J Clin Apher 2019;34(3):171-354

Counts once: this finding and 1 other here come from the same source, so they are one body of evidence, not separate confirmations.

Cognition

Young blood improved memory and synaptic plasticity in aged miceModerate

In plain terms

Old mice given young blood, or plain young plasma, did better on memory tests and showed signs of renewed connections between brain cells. This is the animal result the young-plasma idea is built on.

In detail

Villeda and colleagues (2014) showed that young blood, delivered by heterochronic parabiosis or by repeated intravenous injection of young mouse plasma, reversed several age-related impairments in the aged mouse hippocampus, improving contextual fear conditioning and spatial learning and increasing dendritic spine density and long-term potentiation. The work implicated specific plasma factors in the effect. It is a strong animal signal that plasma constituents can influence brain aging.

The study · 1

Villeda et al., Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice · Nat Med 2014;20(6):659-663

Plasma exchange with albumin slowed Alzheimer decline about 61% in the moderate subgroup (AMBAR)Preliminary

In plain terms

In the one large human trial, plasma exchange with albumin slowed the loss of thinking and everyday function in Alzheimer disease, most clearly in people who were already at a moderate stage. It is one encouraging but mixed result, not a settled treatment.

In detail

Boada and colleagues (2020) reported the AMBAR (Alzheimer Management By Albumin Replacement) trial: 347 patients with mild-to-moderate Alzheimer disease randomized to sham or to plasma exchange with albumin, with or without intravenous immunoglobulin, over 14 months. Treated patients showed less decline on the co-primary endpoints ADAS-Cog (cognition) and ADCS-ADL (daily function); the moderate-disease subgroup showed roughly 61% less functional and cognitive decline versus placebo, while the mild subgroup showed no significant change. The proposed mechanism is removal of albumin-bound amyloid-beta and other plasma factors. Limitations include a single trial, subgroup-dependent effects, and the difficulty of fully blinding an invasive sham procedure.

The study · 1

Boada et al., A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease (AMBAR) · Alzheimers Dement 2020;16(10):1412-1425

Longevity And Mortality

No completed human trial shows young-donor plasma slows agingPreliminary · mixed

In plain terms

In people, there is no finished controlled trial showing that young-donor plasma slows aging or sharpens memory in a healthy person. Scientists are still debating whether the effect, if any, comes from young factors added or old factors removed.

In detail

Una revisión de Kang y colaboradores (2020) examina los factores circulantes implicados en el rejuvenecimiento y describe los dos marcos en competencia, factores beneficiosos juveniles frente a la eliminación o dilución de factores proenvejecimiento, como hipótesis activas respaldadas principalmente por trabajo en roedores. En humanos, la evidencia directa de que el plasma de donante joven ralentice el envejecimiento está ausente; los únicos datos humanos controlados de tamaño considerable sobre el intercambio de plasma en una afección relacionada con el envejecimiento son el ensayo AMBAR de Alzheimer, que usó reemplazo con albúmina, no plasma joven. La infusión comercial de plasma joven para el envejecimiento precedió a cualquier ensayo humano que la respaldara.

The study · 1

Kang & Yang, Circulating plasma factors involved in rejuvenation · Aging (Albany NY) 2020;12(22):23394-23408

Go Deeper

• The biology of aging: where blood-borne factors and plasma exchange sit among the hallmarks of aging, and how to read a mouse rejuvenation result against the human evidence.
• Rapamycin: another longevity frontier where a strong animal record and an approved medical use sit beside a large off-label experiment.
• IV therapy and NAD: a neighboring anti-aging pitch delivered by vein, and the same gap between moving a marker and changing an outcome.
• Peptides: a category where a few approved treatments sit alongside a large unregulated market, and how to tell them apart.

The Chinese Medicine View

Therapeutic plasma exchange is a product of modern transfusion medicine and engineering, with no entry in the classical Chinese pharmacopoeia. No historical text assigns a channel, a temperature, or a flavor to an apheresis procedure, and no traditional practice resembles removing and replacing the fluid of the blood.

Chinese medicine does have a developed theory of Blood, the substance the procedure touches. Blood nourishes the whole body and houses the Shen, the mind and spirit. Classical texts treat Blood as something to conserve and build, and caution against spending it freely.

The two uses look different through that lens:

• When a pathogenic factor drives a disease, removing it echoes the long tradition of clearing what harms so the body can right itself. The caution is that removal also depletes, so it belongs where the need is clear and the person can bear it.
• When the aim is to slow aging in a well person, classical reasoning offers less support. Draining and replacing Blood in someone not deficient breaks the logic of tonification. Tonification helps only where a deficiency already exists, and forcing a healthy system adds no vitality.

Chinese medicine neither endorses nor explains plasma exchange. The evidence for the procedure rests on its own trials, strong for specific diseases and early for aging.

Cautions For This Practice

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

Las reacciones graves de aféresis son poco comunes; el hormigueo por calcio bajo, la presión arterial baja y los desmayos son las habituales

Mortzell Henriksson y colaboradores (2016) reportaron datos actualizados del registro de la World Apheresis Association en muchos miles de procedimientos. Los eventos adversos se registraron en un porcentaje modesto de los procedimientos, dominados por parestesia y tetania relacionadas con el citrato, hipotensión, reacciones vasovagales y reacciones urticariales al líquido de reemplazo; la tasa y la gravedad dependían del líquido de reemplazo (el plasma de donante conlleva más riesgo alérgico que la albúmina) y del estado del paciente. Los eventos graves fueron poco frecuentes. El acceso vascular, en particular los catéteres venosos centrales, aporta riesgos adicionales de infección, sangrado y mecánicos que no se registran como reacciones del procedimiento.Mortzell Henriksson et al., Adverse events in apheresis: An update of the WAA registry data

El citrato en el circuito reduce el calcio, causando hormigueo y calambres a menos que se administre calcio

Zhao y colaboradores (2018) compararon dos métodos de infusión profiláctica de gluconato de calcio durante el intercambio plasmático terapéutico y documentaron la caída esperada en el calcio ionizado plasmático impulsada por la quelación con citrato, junto con la hipocalcemia sintomática que causa cuando no se corrige y su prevención con suplementación de calcio. La toxicidad por citrato es la complicación metabólica más común de la aféresis; generalmente es leve y autolimitada, pero puede progresar a tetania o arritmia con cargas de citrato más altas, razón por la cual se vigila el calcio ionizado durante el intercambio.Zhao & Linden, Prophylactic infusion of calcium gluconate to prevent a symptomatic fall in plasma ionized calcium during therapeutic plasma exchange

A clinical procedure, not a home practice

Plasma exchange requires an apheresis machine, trained staff, large intravenous access, and monitoring. It is done in hospitals and specialist units, and it belongs there. There is no at-home version to arrange on your own. For the established disease uses it is a decision made with the treating team; for aging it is experimental.

The intravenous line and catheter

The procedure needs a large-bore line or a central catheter, and that access carries the clearest risks: local and bloodstream infection, bleeding, and vein injury. Central lines add uncommon but serious events, such as a punctured lung or a clot. The setting and the staff matter as much as the fluid.

Citrate and low calcium

A temporary fall in available calcium is the most common side effect. It shows up as tingling around the mouth and fingers, and if it goes further, muscle cramps or heart-rhythm changes. Units monitor calcium and often give it during the session, and they expect this effect.

Blood pressure, fluid shifts, and reactions

The blood pressure can drop during a session and cause lightheadedness or fainting. Replacement fluids can trigger allergic reactions, more so with donor plasma than with albumin. Removing plasma also removes clotting factors and antibodies the body needs, so repeated sessions can raise bleeding and infection risk until those recover.

Young-donor plasma for aging: a benefit not shown

Clinics have charged thousands of dollars per infusion of young-donor plasma marketed for aging and memory. These infusions carry the ordinary transfusion risks: allergic reactions, infection transmission, and volume overload.

A conversation for a clinician

For the diseases where plasma exchange is standard care, the decision sits with the specialist team treating you. For aging or general wellness, no human trial supports it, so the step that fits the evidence is a conversation with a knowledgeable clinician.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Is plasma exchange a proven treatment?

Yes for the diseases graded first-line, and no for aging. The clearest case is thrombotic thrombocytopenic purpura: once almost always fatal, it became survivable when plasma exchange became standard treatment. A clinic offering the same procedure for aging cannot borrow that record.

Does young blood or plasma slow aging in people?

Not shown. The striking mouse results came from parabiosis, where a young and an old animal were surgically joined to share one blood supply, and no human treatment recreates that. An infusion or an exchange moves fluid for an hour or two; it does not fuse two circulatory systems. That gap is why the mouse rejuvenation does not carry straight over to people.

Can a Chinese herb or formula do what plasma exchange does?

No. An herb or formula adds compounds to the body, while plasma exchange takes molecules out of it. No botanical performs that subtraction.

What are the risks of plasma exchange?

The risks come from the procedure itself: the machine, the large-bore line, and the plasma proteins lost over repeated sessions. The open question is who should accept them. In the established diseases the danger of the illness justifies the risk. In aging, the same procedural risk falls on a well person who has no disease to treat. For healthy aging, the levers with real evidence are free and self-directed: training, sleep, and whole food. Those do more for a well body than an infusion with no completed trial behind it.